Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 4Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 6

Conditions

Neurofibromatosis 1 12Neurofibroma, Plexiform 6Carcinoma, Non-Small-Cell Lung 4Neurofibrosarcoma 3Neoplasms 3Lung Neoplasms 3Melanoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Pain 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Gallbladder Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

AZD 6244 6trametinib 2mirdametinib 2dabrafenib 1cabozantinib 1Liquid Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Neurofibroma, Plexiform × AZD 6244 × 1 year × Clear all
NCT01362803 2026-06-01

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
99 enrolled 1 FDA
CNS

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT06188741 2026-05-29

NF114

University of Alabama at Birmingham

Phase 2 Recruiting
200 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04590235 2026-05-14

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

AstraZeneca

Phase 1 Active not recruiting
32 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04924608 2026-03-23

KOMET

AstraZeneca

Phase 3 Active not recruiting
145 enrolled 17 charts 1 FDA
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06502171 2026-03-12

NF113

University of Alabama at Birmingham

Phase 1 Not yet recruiting
30 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02407405 2026-03-05

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
36 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡